Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
NBIX's Cash-to-Debt is ranked higher than
99% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NBIX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NBIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.72  Med: 47.8 Max: No Debt
Current: No Debt
Interest Coverage No Debt
NBIX's Interest Coverage is ranked higher than
98% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NBIX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NBIX' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: 59.19
Beneish M-Score: -5.35
WACC vs ROIC
12.85%
-2413.34%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1376.31
NBIX's Operating Margin % is ranked lower than
95% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NBIX: -1376.31 )
Ranked among companies with meaningful Operating Margin % only.
NBIX' s Operating Margin % Range Over the Past 10 Years
Min: -17340.03  Med: -982.48 Max: 43.82
Current: -1376.31
-17340.03
43.82
Net Margin % -1334.35
NBIX's Net Margin % is ranked lower than
95% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NBIX: -1334.35 )
Ranked among companies with meaningful Net Margin % only.
NBIX' s Net Margin % Range Over the Past 10 Years
Min: -16936.19  Med: -940.6 Max: 48.53
Current: -1334.35
-16936.19
48.53
ROE % -58.60
NBIX's ROE % is ranked lower than
76% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NBIX: -58.60 )
Ranked among companies with meaningful ROE % only.
NBIX' s ROE % Range Over the Past 10 Years
Min: -250.63  Med: -37.48 Max: 94.61
Current: -58.6
-250.63
94.61
ROA % -51.51
NBIX's ROA % is ranked lower than
71% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NBIX: -51.51 )
Ranked among companies with meaningful ROA % only.
NBIX' s ROA % Range Over the Past 10 Years
Min: -62.22  Med: -28.37 Max: 26.57
Current: -51.51
-62.22
26.57
ROC (Joel Greenblatt) % -3522.63
NBIX's ROC (Joel Greenblatt) % is ranked lower than
81% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NBIX: -3522.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NBIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3522.63  Med: -928.61 Max: 2175.88
Current: -3522.63
-3522.63
2175.88
3-Year Revenue Growth Rate 57.80
NBIX's 3-Year Revenue Growth Rate is ranked higher than
96% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NBIX: 57.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NBIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -100  Med: -10.75 Max: 170.6
Current: 57.8
-100
170.6
3-Year EBITDA Growth Rate 32.00
NBIX's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NBIX: 32.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NBIX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.3  Med: 31.05 Max: 109.6
Current: 32
-64.3
109.6
3-Year EPS without NRI Growth Rate 33.20
NBIX's 3-Year EPS without NRI Growth Rate is ranked higher than
80% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NBIX: 33.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NBIX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.8  Med: 21.05 Max: 66.3
Current: 33.2
-69.8
66.3
GuruFocus has detected 3 Warning Signs with Neurocrine Biosciences Inc $NBIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NBIX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

NBIX Guru Trades in Q2 2016

RS Investment Management 11,090 sh (unchged)
George Soros Sold Out
Pioneer Investments 158,001 sh (-18.15%)
» More
Q3 2016

NBIX Guru Trades in Q3 2016

Jana Partners 96,210 sh (New)
George Soros 11,322 sh (New)
Pioneer Investments 157,165 sh (-0.53%)
» More
Q4 2016

NBIX Guru Trades in Q4 2016

Jana Partners 181,296 sh (+88.44%)
George Soros Sold Out
Pioneer Investments 153,347 sh (-2.43%)
» More
Q1 2017

NBIX Guru Trades in Q1 2017

Steven Cohen 100,000 sh (New)
Jana Partners Sold Out
Pioneer Investments Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NBIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:GLPG, NAS:TECH, NAS:KITE, NAS:IONS, NAS:UTHR, NAS:EXEL, NAS:ACAD, NAS:BLUE, NAS:BIVV, OTCPK:BTGGF, NAS:ALNY, NAS:CBPO, NAS:NKTR, NYSE:XON, NAS:ICPT, OTCPK:ABCZY, NAS:JUNO, NAS:SAGE, NAS:RARE, NAS:LGND » details
Traded in other countries:NB3.Germany,
Headquarter Location:USA
Neurocrine Biosciences Inc discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company has yet to launch a product and continues to accumulate significant operating losses. A now-canceled commercialization agreement with Pfizer accounted for 94% of revenue between 2003 and 2005 in the form of reimbursements and milestone payments.

Guru Investment Theses on Neurocrine Biosciences Inc

Meridian Funds Comments on Neurocrine Biosciences - Aug 31, 2015

Neurocrine Biosciences (NASDAQ:NBIX) is a pharmaceutical company with two development-stage programs focused on neurological and endocrine-based health problems. The company came to our attention after poor clinical trial results for one of its programs resulted in a 40% reduction in the share price. We invested because the issues with the trial were related to trial design, not drug efficacy. Management presented a credible plan for addressing the design issues, and the company’s valuation was capturing only a fraction of the potential cash flows that could be generated by both drug programs. Over the past year, both of Neurocrine’s drug programs have delivered strong clinical trial results and are on track for commercialization, which may drive significant earnings and cash flow growth. We have reduced our position somewhat over the past year due to the strong appreciation in share price but continue to hold shares in Neurocrine Biosciences.



From Meridian Growth Fund’s annual letter.



Check out Meridian Funds latest stock trades

Top Ranked Articles about Neurocrine Biosciences Inc

What Drug Approval Means for Neurocrine Biosciences A secondary catalyst to watch this month
Neurocrine Biosciences (NASDAQ:NBIX) announced in April that the company’s drug Ingrezza (valbenazine) has been approved by the U.S. Food and Drug Administration (FDA) for treating tardive dyskinesia (TD) – a burdensome and often incurable form of dyskinesia. The FDA granted this application Fast Track, Priority Review and Breakthrough Therapy designations. Read more...

Ratios

vs
industry
vs
history
PB Ratio 18.96
NBIX's PB Ratio is ranked lower than
83% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. NBIX: 18.96 )
Ranked among companies with meaningful PB Ratio only.
NBIX' s PB Ratio Range Over the Past 10 Years
Min: 0.9  Med: 6.59 Max: 120
Current: 18.96
0.9
120
EV-to-EBIT -21.73
NBIX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. NBIX: -21.73 )
Ranked among companies with meaningful EV-to-EBIT only.
NBIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -165.9  Med: -4 Max: 426.3
Current: -21.73
-165.9
426.3
EV-to-EBITDA -21.90
NBIX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. NBIX: -21.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
NBIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -636.6  Med: -4.9 Max: 293.3
Current: -21.9
-636.6
293.3
Current Ratio 10.16
NBIX's Current Ratio is ranked higher than
93% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. NBIX: 10.16 )
Ranked among companies with meaningful Current Ratio only.
NBIX' s Current Ratio Range Over the Past 10 Years
Min: 1.63  Med: 9.63 Max: 26.66
Current: 10.16
1.63
26.66
Quick Ratio 10.16
NBIX's Quick Ratio is ranked higher than
94% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. NBIX: 10.16 )
Ranked among companies with meaningful Quick Ratio only.
NBIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.63  Med: 9.63 Max: 26.66
Current: 10.16
1.63
26.66

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.90
NBIX's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. NBIX: -8.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NBIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17  Med: -9 Max: -1.3
Current: -8.9
-17
-1.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 24.17
NBIX's Price-to-Net-Cash is ranked higher than
78% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. NBIX: 24.17 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NBIX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.62  Med: 9.34 Max: 254.67
Current: 24.17
2.62
254.67
Price-to-Net-Current-Asset-Value 23.74
NBIX's Price-to-Net-Current-Asset-Value is ranked lower than
54% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. NBIX: 23.74 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NBIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.79  Med: 6.68 Max: 280
Current: 23.74
1.79
280
Price-to-Tangible-Book 18.94
NBIX's Price-to-Tangible-Book is ranked lower than
78% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. NBIX: 18.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NBIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.11  Med: 4.91 Max: 112.96
Current: 18.94
1.11
112.96
Earnings Yield (Greenblatt) % -4.61
NBIX's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. NBIX: -4.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NBIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.67  Med: 8.6 Max: 3530
Current: -4.61
-4.67
3530

More Statistics

Revenue (TTM) (Mil) $15.00
EPS (TTM) $ -2.31
Beta1.77
Short Percentage of Float7.30%
52-Week Range $37.35 - 55.38
Shares Outstanding (Mil)88.07

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 56 204 406
EPS ($) -1.88 -1.41 0.05
EPS without NRI ($) -1.88 -1.41 0.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NBIX

Headlines

Articles On GuruFocus.com
What Drug Approval Means for Neurocrine Biosciences May 19 2017 
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference May 11 2017 
Neurocrine Biosciences Reports First Quarter 2017 Results May 09 2017 
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results May 03 2017 
Neurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior N May 02 2017 
Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering Apr 26 2017 
Neurocrine Announces Proposed Convertible Senior Notes Offering Apr 25 2017 
Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 Amer Apr 21 2017 
Neurocrine Announces FDA Approval of INGREZZA™ (valbenazine) Capsules as the First and Only Approv Apr 11 2017 
Neurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approv Apr 11 2017 

More From Other Websites
What Drug Approval Means for Neurocrine Biosciences May 19 2017
Neurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to... May 18 2017
AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on... May 17 2017
Edited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT May 15 2017
NBIX: INGREZZA™ Launch Commences… May 11 2017
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference May 11 2017
Neurocrine reports 1Q loss May 09 2017
Neurocrine Biosciences Reports First Quarter 2017 Results May 09 2017
Investor Network: Neurocrine Biosciences, Inc. to Host Earnings Call May 09 2017
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results May 03 2017
Why Neurocrine is charging twice as much for its new drug as it said it would May 03 2017
Neurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior... May 02 2017
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as... May 01 2017
The 3 Best Pharmaceutical Stocks to Buy in 2017 Apr 29 2017
Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering Apr 26 2017
Neurocrine Announces Proposed Convertible Senior Notes Offering Apr 25 2017
Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates Apr 25 2017
Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017... Apr 21 2017
Should You Make a Bet on the Healthcare Stocks? Apr 18 2017
Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug Apr 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat